Takeda Pharmaceutical 관리

관리 기준 확인 2/4

Takeda Pharmaceutical CEO는 Christophe Weber, Jun2014 에 임명되었습니다 의 임기는 10.42 년입니다. 총 연간 보상은 ¥ 2.08B, 15.2% 로 구성됩니다. 15.2% 급여 및 84.8% 보너스(회사 주식 및 옵션 포함). 는 € 20.05M 가치에 해당하는 회사 주식의 0.05% 직접 소유합니다. 20.05M. 경영진과 이사회의 평균 재임 기간은 각각 7.1 년과 8.4 년입니다.

주요 정보

Christophe Weber

최고 경영자

JP¥2.1b

총 보상

CEO 급여 비율	15.2%
CEO 임기	10.4yrs
CEO 소유권	0.05%
경영진 평균 재임 기간	7.1yrs
이사회 평균 재임 기간	8.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Christophe Weber 의 보수는 Takeda Pharmaceutical 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	JP¥290b
Jun 30 2024	n/a	n/a	JP¥150b
Mar 31 2024	JP¥2b	JP¥317m	JP¥144b
Dec 31 2023	n/a	n/a	JP¥178b
Sep 30 2023	n/a	n/a	JP¥192b
Jun 30 2023	n/a	n/a	JP¥301b
Mar 31 2023	JP¥2b	JP¥295m	JP¥317b
Dec 31 2022	n/a	n/a	JP¥275b
Sep 30 2022	n/a	n/a	JP¥213b
Jun 30 2022	n/a	n/a	JP¥197b
Mar 31 2022	JP¥2b	JP¥281m	JP¥230b
Dec 31 2021	n/a	n/a	JP¥439b
Sep 30 2021	n/a	n/a	JP¥473b
Jun 30 2021	n/a	n/a	JP¥431b
Mar 31 2021	JP¥2b	JP¥267m	JP¥376b
Dec 31 2020	n/a	n/a	JP¥181b
Sep 30 2020	n/a	n/a	JP¥56b
Jun 30 2020	n/a	n/a	JP¥120b
Mar 31 2020	JP¥2b	JP¥273m	JP¥44b
Dec 31 2019	n/a	n/a	JP¥13b
Sep 30 2019	n/a	n/a	JP¥83b
Jun 30 2019	n/a	n/a	JP¥64b
Mar 31 2019	JP¥2b	JP¥269m	JP¥135b
Dec 31 2018	n/a	n/a	JP¥110b
Sep 30 2018	n/a	n/a	JP¥141b
Jun 30 2018	n/a	n/a	JP¥120b
Mar 31 2018	JP¥1b	JP¥254m	JP¥187b

보상 대 시장: Christophe 의 총 보상 ($USD 13.45M )은 German 시장( $USD 4.77M ).

보상과 수익: Christophe 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Christophe Weber (58 yo)

10.4yrs

테뉴어

JP¥2,083,000,000

보상

Mr. Christophe Weber has been the President and Chief Executive Officer of Takeda Pharmaceutical Company Limited since June 27, 2014 and April 2015 respectively and served as its Chief Operating Officer fr...

리더십 팀

이름	위치	테뉴어	보상	소유권
Christophe Weber	President	10.4yrs	JP¥2.08b	0.050% € 20.0m
Seigo Izumo	Chair of Management Board	no data	데이터 없음	데이터 없음
Milano Furuta	CFO & Director	less than a year	데이터 없음	0.00083% € 335.6k
Haruhiko Hirate	Member of Management Board	no data	데이터 없음	데이터 없음
Salvatore Alesci	Member of Management Board and Head of R&D Global Science & Biomedical Policy	no data	데이터 없음	데이터 없음
Norimasa Takeda	Chief Accounting Officer & Corporate Controller	no data	데이터 없음	데이터 없음
Iwaaki Taniguchi	Senior Vice President of Corporate Finance & Controlling Department	11.7yrs	데이터 없음	데이터 없음
Gabriele Ricci	Chief Data & Technology Officer	2.8yrs	데이터 없음	데이터 없음
Christopher David O'Reilly	Global Head of Investor Relations & Global Finance	4.2yrs	데이터 없음	데이터 없음
Yoshihiro Nakagawa	Global General Counsel	10.1yrs	데이터 없음	데이터 없음
Mwana Lugogo	Chief Ethics & Compliance Officer	10.1yrs	데이터 없음	데이터 없음
Lauren Duprey	Chief Human Resources Officer	3.8yrs	데이터 없음	데이터 없음

7.1yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 관리: TKD 의 관리팀은 노련하고 경험 (평균 재직 기간 7.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Christophe Weber	President	10.4yrs	JP¥2.08b	0.050% € 20.0m
Milano Furuta	CFO & Director	no data	데이터 없음	0.00083% € 335.6k
Andrew S. Plump	President of Research & Development and Representative Director	9.4yrs	JP¥972.00m	0.0087% € 3.5m
John M. Maraganore	Independent External Director	2.4yrs	JP¥32.00m	데이터 없음
Steven S. Gillis	Independent External Director	5.8yrs	JP¥44.00m	0.00026% € 105.1k
Emiko Higashi	Independent External Director	8.4yrs	JP¥49.00m	0.00016% € 64.7k
Yoshiaki Fujimori	Independent External Director	8.4yrs	JP¥40.00m	0.00079% € 319.4k
Ian T. Clark	Independent External Director	5.8yrs	JP¥44.00m	0.000070% € 28.3k
Jean-Luc Butel	Independent External Director	5.4yrs	JP¥38.00m	데이터 없음
Michel Orsinger	Independent External Director	8.4yrs	JP¥46.00m	데이터 없음
Masami Iijima	Independent External Chair	3.4yrs	JP¥43.00m	0.000020% € 8.1k
Koji Hatsukawa	Independent External Director	8.4yrs	JP¥43.00m	0.00063% € 254.7k

8.4yrs

평균 재임 기간

66.5yo

평균 연령

경험이 풍부한 이사회: TKD 의 이사회는 경험(평균 재직 기간 8.4 년)으로 간주됩니다.

Takeda Pharmaceutical 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda Pharmaceutical Company Limited Announces Board Changes

Recent updates

Second quarter 2025 earnings released: EPS: JP¥58.15 (vs JP¥30.68 loss in 2Q 2024)

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Upcoming dividend of JP¥98.00 per share

Takeda Receives European Commission Approval for ADZYNMA®

First quarter 2025 earnings released: EPS: JP¥60.71 (vs JP¥57.51 in 1Q 2024)

Final dividend of JP¥98.00 announced

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Full year 2024 earnings released: EPS: JP¥92.09 (vs JP¥204 in FY 2023)

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Full year 2024 earnings released: EPS: JP¥92.09 (vs JP¥204 in FY 2023)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Upcoming dividend of JP¥94.00 per share

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

New major risk - Financial position

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Second quarter 2024 earnings released: JP¥30.68 loss per share (vs JP¥39.77 profit in 2Q 2023)

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Upcoming dividend of JP¥94.00 per share at 3.9% yield

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: JP¥204 (vs JP¥147 in FY 2022)

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령